G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement